When a woman is diagnosed with mixed endometrial carcinoma, her tumor contains more than one cell type. Standard practice is to test the whole tumor as one sample. But new research suggests that testing each component separately might reveal important differences.
In a small study of 8 patients, researchers analyzed the endometrioid and serous or clear cell components separately. In 2 cases, the serous component had a POLE mutation and abnormal p53, while the endometrioid part did not. This could change risk assessment: the serous component might be higher risk than the endometrioid part suggests.
However, this is a hypothesis-generating analysis with only 8 cases and no follow-up data. The findings are preliminary and need confirmation in larger studies. The researchers caution that the observations come from a single sample and should be interpreted carefully.
For now, the takeaway is that separate profiling might offer more precise risk information, but it's too early to change practice. Women with mixed endometrial cancer should discuss their specific case with their oncologist.